Amarin Appeals FDA Ruling On Fish Oil Drug's Expansion

Law360, San Francisco (November 8, 2013, 6:10 PM EST) -- Amarin Corp. PLC on Thursday appealed a U.S. Food and Drug Administration panel's denial of expanded use of its fish oil drug Vascepa among adults with high cholesterol levels, saying in a federal filing that the denial would harm the company's financial condition.

In its quarterly report to the U.S. Securities and Exchange Commission, Amarin said that it is uncertain whether its appeal, in which it argues why it believes the FDA was wrong to rescind Vascepa's expansion, will be successful.

“There can be no assurance...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.